IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Accretion Pharmaceuticals IPO is a book build IPO listing on NSE EMERGE exchange. The company is based in Ahmedabad and caters to Pharmaceutical sector. Jawa Capital Services Private is the merchant banker of Accretion Pharmaceuticals IPO. It is a SME UPCOMING IPO which filed its Draft Red Herring Prospectus (DRHP) on 8th January 2025.
Accretion Pharmaceuticals IPO posted revenues of Rs 35.67 crores and PAT of Rs 4.71 crores in FY25 on annualised basis.Financial results of Accretion Pharmaceuticals IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Accretion Pharmaceuticals IPO PAT Margin is 13.23%, ROCE (Return on Capital Employed) is 12.23% as per latest financial. The below table shows Accretion Pharmaceuticals IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Accretion Pharmaceuticals IPO is Rs [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Accretion Pharmaceuticals IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Accretion Pharmaceuticals IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Accretion Pharmaceuticals IPO is ₹[●] Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Accretion Pharmaceuticals IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Accretion Pharmaceuticals IPO reported revenue of ₹35.67 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Accretion Pharmaceuticals IPO provide insights into sales growth, market demand, and business scalability.
Accretion Pharmaceuticals recorded an EBITDA of ₹ 7.92 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Accretion Pharmaceuticals Profit After Tax (PAT) is ₹4.71 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 35.61 Cr.
EBITDA Margin:
22.24
%
Net Worth: ₹ 9.91 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: [●]
Accretion Pharmaceuticals operates in Pharmaceutical and . The Issue is listed on NSE EMERGE in Apr, 2025. Accretion Pharmaceuticals IPO size was with Issue price of .
Merchant Banker(s) of Accretion Pharmaceuticals IPO: Jawa Capital Services Private Limited
Accretion Pharmaceuticals IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Accretion Pharmaceuticals IPO listed at a listing price of against the offer price of .
The current market price of Accretion Pharmaceuticals is .
Why Us?
